Atomo Diagnostics CEO John Kelly. Credit: Atomo Diagnostics.

Australia-based design company Atomo Diagnostics has partnered with US-based rapid diagnostics developer Access Bio to expand point of care testing for HIV in international markets.

As part of the strategic alliance, Access Bio will leverage Atomo Diagnostics’ all-in-one AtomoRapid lateral flow diagnostic test platforms for its in-vitro rapid test.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The test has been designed to identify HIV antibodies in blood and deliver results within minutes to ensure early diagnosis and treatment.

Atomo Diagnostics founder and CEO John Kelly said: “Our AtomoRapid platforms are proving their excellent usability and performance for a range of applications internationally, and this new partnership adds significantly to our long-term growth plans.

“Moreover, it demonstrates our continued commitment to tackling HIV by enabling greater access to best-in-class diagnostics in areas hardest hit by the disease.”

Access Bio will commercialise the new test under its CareStart brand in professional use markets of Africa, South East Asia, South America, and CIS countries.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“It demonstrates our continued commitment to tackling HIV by enabling greater access to best-in-class diagnostics in areas hardest hit by the disease.”

The test is expected to bolster the firm’s rapid test portfolio and support continued growth.

Access Bio founder and CEO Young Ho Choi said: “Access Bio’s HIV test strips combined with Atomo’s test devices will also offer an innovative solution to support the HIV 90-90-90 campaign.

“This alliance with Atomo is highly compatible with our established business channels, and we are actively exploring other areas of collaboration to strengthen our portfolio in the mid-to-long term.”

The firm and its subsidiary Wells Bio produce more than 120 million rapid diagnostic tests per year to detect various infectious diseases such as malaria, dengue, and HIV.